Paracervical Block in Laparoscopic Hysterectomy

Learn more about:
Related Clinical Trial
Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Paracervical Block in Laparoscopic Hysterectomy

Official Title

A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Paracervical Block Before Total Laparoscopic Hysterectomy for Postoperative Pain Control (PALAPA):

Brief Summary

      It remains controversial whether paracervical block should be performed as a powerful
      strategy for pain relief in total laparoscopic hysterectomy (TLH), because convincing
      conclusions are difficult to draw because of the heterogeneous and contradictory nature of
      the literature. Therefore, the aim of this study was to evaluate the efficacy of paracervical
      blocks using with 0.5% bupivacaine prior to TLHs for benign gynecologic conditions on
      postoperative pain relief.
    

Detailed Description

      Postoperative pain management is an important component of patient care and satisfaction
      after surgery. Although contemporary changes such as a shift to minimally invasive approaches
      and an introduction of the enhanced recovery after surgery (ERAS) program have resulted in
      improved outcomes, a large number of patients undergoing surgery have still inadequate pain
      control. Paracervical block is a single-injection of anesthetic around the cervix at a depth
      of about 1 cm, diffusing anesthetic into the second to fourth sacral nerve roots passing
      through Frankenhäuser plexus. Moreover, recent randomized trials demonstrated that patients
      who underwent vaginal hysterectomy and received a paracervical block had lower postoperative
      pain in the first 3-6 hours compared with placebo.

      However, it remains controversial whether paracervical block should be performed as a
      powerful strategy for pain relief in total laparoscopic hysterectomy (TLH), because
      convincing conclusions are difficult to draw because of the heterogeneous and contradictory
      nature of the literature. Therefore, the aim of this study was to evaluate the efficacy of
      paracervical blocks using with 0.5% bupivacaine prior to TLHs for benign gynecologic
      conditions on postoperative pain relief.
    


Study Type

Interventional


Primary Outcome

Postoperative pain

Secondary Outcome

 Frequency of pills/injections requested

Condition

Uterine Fibroid

Intervention

Paracervical block

Study Arms / Comparison Groups

 Paracervical block with 5% bupivacaine
Description:  The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Device

Estimated Enrollment

86

Start Date

February 21, 2019

Completion Date

February 1, 2021

Primary Completion Date

February 1, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  age between 18 and 65 years

          -  American Society of Anesthesiologists physical status (ASAPS) classification I-II

          -  the absence of pregnancy at the time of surgery

        Exclusion Criteria:

          -  history of cervical surgery such as conization or cerclage

          -  inability to perform the paracervical block due to anatomical abnormalities (i.e.,
             very atrophic or small cervix)

          -  allergy to bupivacaine, planned concomitant surgical procedures involving extensive
             additional tissue manipulation such as pelvic lymph node dissection

          -  any concomitant surgery of pelvic floor repair (uterosacral ligament suspension or
             sacrocolpopexy) or vaginal procedures (anterior or posterior colporrhaphy or
             mid-urethral slings), previously taking opioids for chronic pain

          -  inability to accurately express their pain
      

Gender

Female

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Taejong Song, M.D., Ph.D., +821040358405, [email protected]

Location Countries

Korea, Republic of

Location Countries

Korea, Republic of

Administrative Informations


NCT ID

NCT03792009

Organization ID

2019-01-001


Responsible Party

Principal Investigator

Study Sponsor

Kangbuk Samsung Hospital


Study Sponsor

Taejong Song, M.D., Ph.D., Principal Investigator, Kangbuk Samsung Hospital


Verification Date

February 2019